Thursday 16 October, 2025
Objectives: Developed vaccines against SARS-CoV-2 have been a turning point against the ongoing Covid-19 pandemic by dramatically reducing the number…
Read moreAbstracts
Expanding a quantitative systems pharmacology (QSP) modeling framework for acute Hepatitis B to characterize chronic infection
Thursday 16 October, 2025
Objectives: Chronic hepatitis B virus (HBV) infection is associated with high morbidity and mortality and represents an unmet medical need…
Read moreTranslational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections
Thursday 16 October, 2025
Objectives: Apramycin (EBL-1003) is a broad-spectrum aminoglycoside antibiotic for the treatment of gram-negative bacteria infections that is currently under development for…
Read morePopulation pharmacokinetic modelling to characterize (es)citalopram exposure in a large cohort of psychiatric patients
Thursday 16 October, 2025
Objectives: Citalopram is the racemic combination of R and S-citalopram (escitalopram), the latter being the active form. Both enantiomers are mainly…
Read moreUnlocking Diversity: Towards a Comprehensive Framework for Physiologically Based Pharmacokinetic Population Qualification in Sub Saharan Africa
Thursday 16 October, 2025
Objectives: Characterize a population Gather CYP450 enzyme activity phenotype data from SSA Subdivision of SSA into regions and statistically compare…
Read moreComparing the objective function value in NONMEM is valid for model selection when fixing THETA or OMEGA but not when fixing ETAs
Thursday 16 October, 2025
Introduction: In population PKPD modeling a common aim is to use models to make predictions on quantities of interest of…
Read moreIn vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate.
Thursday 16 October, 2025
Objectives: Antimicrobial combination therapy offers an option for increasing efficacy and prevention against the emergence of resistance. Synergy between meropenem (MER)…
Read moreA pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro.
Thursday 16 October, 2025
Objectives: Emerging resistance to last-line antibiotics in multidrug-resistant K. pneumoniae has led to exploration of phage therapy as promising, non-traditional alternative. However,…
Read moreMachine learning-driven flattening of model priors: A comparative simulation study across multiple compounds
Thursday 16 October, 2025
Introduction Model-informed precision dosing (MIPD) supports clinical decision-making by leveraging mathematical models and individual drug or biomarker measurements [1]. A…
Read moreFacilitating structural population PK model building for pharmacometricians and beyond
Thursday 16 October, 2025
Introduction: Population pharmacokinetic (PK) analyses not only require a pharmacometric understanding but also a decent knowledge of the software used…
Read more